KLK3 and posterior cortical atrophy: Patients from the SPIRIT trial who had favorable risk PCa (T1-T2a, PSA ≤10 ng/ml, Gleason score ≤6, were candidates for both RP and LDR-BT; had prostate volume <60 cm3, Eastern Cooperative Oncology Group performance status 0–2 and with no major medical comorbidities.